135 related articles for article (PubMed ID: 37390473)
1. Cinobufagin: a promising therapeutic agent for cancer.
Dai CL; Zhang RJ; An P; Deng YQ; Rahman K; Zhang H
J Pharm Pharmacol; 2023 Sep; 75(9):1141-1153. PubMed ID: 37390473
[TBL] [Abstract][Full Text] [Related]
2. Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and invasion by inhibiting G9a in non-small-cell lung cancer A549 cells.
Zhang L; Liang B; Xu H; Gong Y; Hu W; Jin Z; Wu X; Chen X; Li M; Shi L; Shi Y; Wang Y; Yang L
J Ethnopharmacol; 2022 Jun; 291():115095. PubMed ID: 35176466
[TBL] [Abstract][Full Text] [Related]
3. [Research progress in quality control of Bufonis Venenum in preparations].
Wang YX; Wang PF; Fang YG; Liu YT; Chen LM; Wang ZM; Gao HM
Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(17):4552-4568. PubMed ID: 37802796
[TBL] [Abstract][Full Text] [Related]
4. Metabolites from Bufo gargarizans (Cantor, 1842): A review of traditional uses, pharmacological activity, toxicity and quality control.
Zhan X; Wu H; Wu H; Wang R; Luo C; Gao B; Chen Z; Li Q
J Ethnopharmacol; 2020 Jan; 246():112178. PubMed ID: 31445132
[TBL] [Abstract][Full Text] [Related]
5. Study on anti-osteosarcoma activity of ethanol extract of Venenum bufonis in vitro.
Chen G; Jiang X; Li J; Duan G; Yang L; Zhang Y; Wang F
Afr J Tradit Complement Altern Med; 2014; 11(1):73-7. PubMed ID: 24653556
[TBL] [Abstract][Full Text] [Related]
6. [Systematic comparison of two kinds of Bufonis Venenum derived from different Bufo gargarizans subspecies based on metabolomics and antitumor activity].
Sun B; Li ML; Ding YH; Zhang Y; Xia B; Guo SY; Wang SL; Bian BL; Si N; Zhao HY
Zhongguo Zhong Yao Za Zhi; 2023 Mar; 48(5):1280-1288. PubMed ID: 37005812
[TBL] [Abstract][Full Text] [Related]
7. Uncovering the Mechanisms of Active Components from Toad Venom against Hepatocellular Carcinoma Using Untargeted Metabolomics.
Liang P; Ma Y; Yang L; Mao L; Sun Q; Sun C; Liu Z; Mazhar M; Yang S; Ren W
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431859
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor.
Qi F; Li A; Inagaki Y; Kokudo N; Tamura S; Nakata M; Tang W
Int Immunopharmacol; 2011 Mar; 11(3):342-9. PubMed ID: 21185919
[TBL] [Abstract][Full Text] [Related]
9. Identification of Antitumor Constituents in Toad Venom by Spectrum-Effect Relationship Analysis and Investigation on Its Pharmacologic Mechanism.
Wu JH; Cao YT; Pan HY; Wang LH
Molecules; 2020 Sep; 25(18):. PubMed ID: 32961837
[TBL] [Abstract][Full Text] [Related]
10. [Effect of origin species, body weight, and gender on quality of Bufonis Venenum].
Gao ZY; Jiang P; Zhan CS
Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(22):6034-6041. PubMed ID: 36471927
[TBL] [Abstract][Full Text] [Related]
11. Study of Cinobufagin as a Promising Anticancer Agent in Uveal Melanoma Through Intrinsic Apoptosis Pathway.
Zhang L; Huang X; Guo T; Wang H; Fan H; Fang L
Front Oncol; 2020; 10():325. PubMed ID: 32300551
[TBL] [Abstract][Full Text] [Related]
12. Cinobufagin induces cell cycle arrest at the S phase and promotes apoptosis in nasopharyngeal carcinoma cells.
Pan Z; Luo Y; Xia Y; Zhang X; Qin Y; Liu W; Li M; Liu X; Zheng Q; Li D
Biomed Pharmacother; 2020 Feb; 122():109763. PubMed ID: 31918288
[TBL] [Abstract][Full Text] [Related]
13. [Determination of resibufogenin and cinobufagin in venenum Bufonis by HPLC].
Wang J; Jin W; Jin H; Zhou F
Zhongguo Zhong Yao Za Zhi; 1998 Nov; 23(11):651-3, 702. PubMed ID: 11599342
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of fourteen bufadienolides in Venenum Bufonis crude drug and its Chinese patent medicines by ultra-high performance liquid chromatography coupled with tandem mass spectrometry.
Wei WL; An YL; Zhang YZ; Li ZW; Zhou Y; Lei M; Zhang JQ; Qu H; Da J; Wu WY; Guo DA
J Ethnopharmacol; 2020 Apr; 251():112490. PubMed ID: 31884035
[TBL] [Abstract][Full Text] [Related]
15. [Correlative study of bufogenin constituents in venom of Bufo bufo gargarizans].
Cao YT; Cui KK; Wu JH; Pan HY; Lu ZY; Shao JF; Wang LH
Zhongguo Zhong Yao Za Zhi; 2019 May; 44(9):1850-1856. PubMed ID: 31342712
[TBL] [Abstract][Full Text] [Related]
16. Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase.
Yang A; Wu Q; Chen Q; Yang J; Li H; Tao Y; Wang A; Sun Y; Zhang J
Chem Biol Interact; 2022 Jun; 360():109938. PubMed ID: 35427566
[TBL] [Abstract][Full Text] [Related]
17. Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15 cells.
Cui X; Inagaki Y; Xu H; Wang D; Qi F; Kokudo N; Fang D; Tang W
Biol Pharm Bull; 2010; 33(10):1728-32. PubMed ID: 20930383
[TBL] [Abstract][Full Text] [Related]
18. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.
Zhang DM; Liu JS; Tang MK; Yiu A; Cao HH; Jiang L; Chan JY; Tian HY; Fung KP; Ye WC
Eur J Pharmacol; 2012 Oct; 692(1-3):19-28. PubMed ID: 22841670
[TBL] [Abstract][Full Text] [Related]
19. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
Yang AL; Wu Q; Hu ZD; Wang SP; Tao YF; Wang AM; Sun YX; Li XL; Dai L; Zhang J
Toxicol Appl Pharmacol; 2021 Nov; 431():115739. PubMed ID: 34619160
[TBL] [Abstract][Full Text] [Related]
20. [Molecular identification of animal species of Bufonis Venenum from secretions].
Li HY; Liu J; Liang XC; Wang YL; Meng YC; Chen WC; Huang Y
Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(1):80-87. PubMed ID: 38403341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
